vs

Side-by-side financial comparison of Northfield Bancorp, Inc. (NFBK) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

Northfield Bancorp, Inc. is the larger business by last-quarter revenue ($41.3M vs $35.5M, roughly 1.2× RECURSION PHARMACEUTICALS, INC.). RECURSION PHARMACEUTICALS, INC. runs the higher net margin — -304.2% vs -1545.5%, a 1241.3% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 12.7%). Northfield Bancorp, Inc. produced more free cash flow last quarter ($52.5M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 15.0%).

Northfield Bancorp, Inc. is a regional bank holding company based in the United States, operating primarily across the U.S. Northeast region. It provides a full range of personal and commercial banking services including deposit accounts, mortgage loans, commercial lending, and wealth management solutions for retail consumers, small to medium-sized businesses and local community clients.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

NFBK vs RXRX — Head-to-Head

Bigger by revenue
NFBK
NFBK
1.2× larger
NFBK
$41.3M
$35.5M
RXRX
Growing faster (revenue YoY)
RXRX
RXRX
+669.1% gap
RXRX
681.7%
12.7%
NFBK
Higher net margin
RXRX
RXRX
1241.3% more per $
RXRX
-304.2%
-1545.5%
NFBK
More free cash flow
NFBK
NFBK
$99.9M more FCF
NFBK
$52.5M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
15.0%
NFBK

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
NFBK
NFBK
RXRX
RXRX
Revenue
$41.3M
$35.5M
Net Profit
$-27.4M
$-108.1M
Gross Margin
59.8%
Operating Margin
-1263.3%
-304.8%
Net Margin
-1545.5%
-304.2%
Revenue YoY
12.7%
681.7%
Net Profit YoY
-343.6%
39.6%
EPS (diluted)
$-0.68
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NFBK
NFBK
RXRX
RXRX
Q4 25
$41.3M
$35.5M
Q3 25
$39.2M
$5.2M
Q2 25
$38.9M
$19.2M
Q1 25
$34.8M
$14.7M
Q4 24
$36.7M
$4.5M
Q3 24
$31.8M
$26.1M
Q2 24
$31.5M
$14.4M
Q1 24
$31.3M
$13.8M
Net Profit
NFBK
NFBK
RXRX
RXRX
Q4 25
$-27.4M
$-108.1M
Q3 25
$10.8M
$-162.3M
Q2 25
$9.6M
$-171.9M
Q1 25
$7.9M
$-202.5M
Q4 24
$11.3M
$-178.9M
Q3 24
$6.5M
$-95.8M
Q2 24
$6.0M
$-97.5M
Q1 24
$6.2M
$-91.4M
Gross Margin
NFBK
NFBK
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
NFBK
NFBK
RXRX
RXRX
Q4 25
-1263.3%
-304.8%
Q3 25
37.7%
-3327.6%
Q2 25
35.6%
-916.8%
Q1 25
31.0%
-1297.9%
Q4 24
38.0%
-4042.4%
Q3 24
27.9%
-377.1%
Q2 24
29.1%
-697.4%
Q1 24
27.2%
-698.4%
Net Margin
NFBK
NFBK
RXRX
RXRX
Q4 25
-1545.5%
-304.2%
Q3 25
27.4%
-3135.3%
Q2 25
24.6%
-894.2%
Q1 25
22.6%
-1373.3%
Q4 24
30.7%
-3935.5%
Q3 24
20.5%
-367.5%
Q2 24
18.9%
-676.6%
Q1 24
19.9%
-662.4%
EPS (diluted)
NFBK
NFBK
RXRX
RXRX
Q4 25
$-0.68
$-0.17
Q3 25
$0.27
$-0.36
Q2 25
$0.24
$-0.41
Q1 25
$0.19
$-0.50
Q4 24
$0.27
$-0.56
Q3 24
$0.16
$-0.34
Q2 24
$0.14
$-0.40
Q1 24
$0.15
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NFBK
NFBK
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$164.0M
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$690.1M
$1.1B
Total Assets
$5.8B
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NFBK
NFBK
RXRX
RXRX
Q4 25
$164.0M
$743.3M
Q3 25
$131.7M
$659.8M
Q2 25
$97.6M
$525.1M
Q1 25
$101.7M
$500.5M
Q4 24
$167.7M
$594.4M
Q3 24
$232.9M
$427.6M
Q2 24
$153.5M
$474.3M
Q1 24
$238.8M
$296.3M
Total Debt
NFBK
NFBK
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$666.4M
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
NFBK
NFBK
RXRX
RXRX
Q4 25
$690.1M
$1.1B
Q3 25
$719.6M
$1.0B
Q2 25
$710.3M
$919.1M
Q1 25
$711.1M
$933.9M
Q4 24
$704.7M
$1.0B
Q3 24
$699.6M
$524.6M
Q2 24
$693.0M
$584.4M
Q1 24
$698.4M
$401.2M
Total Assets
NFBK
NFBK
RXRX
RXRX
Q4 25
$5.8B
$1.5B
Q3 25
$5.7B
$1.4B
Q2 25
$5.7B
$1.3B
Q1 25
$5.7B
$1.3B
Q4 24
$5.7B
$1.4B
Q3 24
$5.7B
$726.5M
Q2 24
$5.7B
$775.9M
Q1 24
$5.9B
$557.8M
Debt / Equity
NFBK
NFBK
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.95×
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NFBK
NFBK
RXRX
RXRX
Operating Cash FlowLast quarter
$53.7M
$-46.1M
Free Cash FlowOCF − Capex
$52.5M
$-47.3M
FCF MarginFCF / Revenue
127.1%
-133.1%
Capex IntensityCapex / Revenue
2.8%
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$89.2M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NFBK
NFBK
RXRX
RXRX
Q4 25
$53.7M
$-46.1M
Q3 25
$13.9M
$-117.4M
Q2 25
$14.1M
$-76.4M
Q1 25
$9.4M
$-132.0M
Q4 24
$31.1M
$-115.4M
Q3 24
$14.0M
$-59.2M
Q2 24
$6.9M
$-82.2M
Q1 24
$4.2M
$-102.3M
Free Cash Flow
NFBK
NFBK
RXRX
RXRX
Q4 25
$52.5M
$-47.3M
Q3 25
$13.6M
$-117.6M
Q2 25
$13.9M
$-79.6M
Q1 25
$9.2M
$-133.8M
Q4 24
$30.0M
$-116.7M
Q3 24
$13.7M
$-63.8M
Q2 24
$6.7M
$-83.4M
Q1 24
$3.8M
$-109.0M
FCF Margin
NFBK
NFBK
RXRX
RXRX
Q4 25
127.1%
-133.1%
Q3 25
34.6%
-2272.5%
Q2 25
35.7%
-413.9%
Q1 25
26.3%
-907.4%
Q4 24
81.6%
-2567.7%
Q3 24
43.2%
-244.6%
Q2 24
21.1%
-578.5%
Q1 24
12.1%
-789.9%
Capex Intensity
NFBK
NFBK
RXRX
RXRX
Q4 25
2.8%
3.5%
Q3 25
0.8%
4.7%
Q2 25
0.6%
16.4%
Q1 25
0.7%
12.4%
Q4 24
3.1%
28.6%
Q3 24
0.7%
17.5%
Q2 24
0.8%
8.2%
Q1 24
1.4%
48.2%
Cash Conversion
NFBK
NFBK
RXRX
RXRX
Q4 25
Q3 25
1.29×
Q2 25
1.48×
Q1 25
1.20×
Q4 24
2.76×
Q3 24
2.14×
Q2 24
1.16×
Q1 24
0.68×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons